Common Contracts
6 similar null contracts by BioVex Group, Inc., Cardiac Science Inc, Gensia Sicor Inc, others
Exhibit 10.8.2 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT...BioVex Group, Inc. • August 31st, 2006 • Biological products, (no disgnostic substances) • Massachusetts
EXHIBIT 4.2 THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR SALE IN CONNECTION WITH, THE DISTRIBUTION THEREOF. THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND...Cardiac Science Inc • June 6th, 2002 • Electromedical & electrotherapeutic apparatus • New York
1 EXHIBIT 10.13 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION...Saleslogix Corp • March 30th, 2000 • Services-prepackaged software • New York
DEMAND NOTESuperconductor Technologies Inc • March 30th, 2000 • Services-commercial physical & biological research
FORM OF C NOTE] THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, as AMENDED, or any state SECURITIES laws, AND MAY NOT BE OFFERED OR SOLD, UNLESS IT HAS BEEN REGISTERED UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR...Party City Corp • August 25th, 1999 • Retail-miscellaneous shopping goods stores • New York
GENSIA SICOR INC. 2.675% Subordinated Convertible Notes due May 1, 2004Gensia Sicor Inc • August 14th, 1997 • Pharmaceutical preparations
GENSIA SICOR INC. (the "Company"), a Delaware corporation, for value received, hereby promises to pay to [HEALTH CARE CAPITAL PARTNERS, L.P.], or registered assigns, the principal amount of TWENTY MILLION AND 00/100 DOLLARS [$20,000,000.00] on May 1, 2004, with interest (computed on the basis of a 360- day year of twelve 30-day months) on the unpaid balance of such principal amount at the rate of 2.675% per annum from the date hereof, payable quarterly, in arrears, on the last business day of March, June, September and December, until such unpaid balance shall become due and payable (whether at maturity or at a date fixed for redemption or by declaration or otherwise). During the continuance of any Default or Event of Default, the Company shall pay interest on the outstanding principal of, and any other amounts (other than interest), if any, due on the Notes and (to the extent legally enforceable) on any overdue installment of interest, at the rate of 11.75% per annum (computed on the
